Navigation Links
Study Reaffirms Superiority of Trofile(TM) Assay
Date:12/19/2007

termines whether a patient is infected with a strain of HIV that uses either the CCR5 coreceptor, the CXCR4 coreceptor, or a combination of CCR5 and CXCR4 to enter cells. The use of CCR5, CXCR4 or both coreceptors defines the "tropism" of the virus strain. Trofile amplifies the envelope gene from a patient's HIV genome (from their blood sample) and then uses it to make HIV particles containing the patient's virus envelope protein. The resultant HIV particles are then used to infect cells that contain the CCR5 co-receptor or the CXCR4 co- receptor on the cell surface. Once the virus infects the cell, it undergoes a single round of replication. Virus replication results in the production of luciferase from a luciferase gene that is carried into the cell by the virus. The production of luciferase in either CCR5 cells, CXCR4 cells or both cell types defines the co-receptor tropism of the patient virus.

Trofile has been used to select patients in all phase II and phase III studies of CCR5 antagonists to date. Data from Pfizer's phase III trials of maraviroc indicate that patients identified as being CCR5 tropic by Trofile achieved a significant reduction in viral load when maraviroc was added to an optimized background therapy, while patients identified by Trofile as CXCR4 or dual/mixed (CXCR4/CCR5) achieved no significant reduction in viral load when treated with maraviroc plus an optimized background regimen.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Nashville Fertility ... was elected treasurer for the American Society for Reproductive ... knowledge and research in reproductive medicine. In his ... seat on the executive board and will have a ... Dr. Hill has actively supported ASRM since 1984 when ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today ... & Company, LLP as its independent registered public ... the Company,s independent registered public accounting firm was ... The appointment will result in cost savings for ...
... AND EUROPE FOR TECHNOLOGY USED IN CORGENIX NEXT ... Corgenix Medical Corporation (OTC Bulletin Board: CONX), ... kits, has received notification of two new patents ... licensing rights outside of Japan. The technology ...
... 20 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd., ... drugs to treat infectious diseases, cancer and diabetes-related ... USD through the private placement of preferred C ... including MPM Capital, National Development Fund, YFY group, ...
Cached Biology Technology:Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm 2Corgenix Receives Two Additional Patents on AtherOx(R) Technology 2Corgenix Receives Two Additional Patents on AtherOx(R) Technology 3TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing 2
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... of Manchester funded by the Fungal Research Trust have ... - in our pillows. , ... pillows, is most likely to cause disease; and the ... of death in leukaemia and bone marrow transplant patients. ...
... Left untreated, prostate cancer cells often metastasize, or spread, ... extremely painful. , More than 80 percent of ... disease in their bones. But scientists know very little ... in bone tissue and produce the dense bony lesions ...
... money from Johns Hopkins Institute of Cell Engineering, a Johns ... between the health of stem cells and the length of ... are repetitive stretches of DNA that protect chromosomes in much ... fabric from fraying. Each time a cell divides, its chromosome ...
Cached Biology News:Pillows - a hot bed of fungal spores 2Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 2Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 3A little telomerase isn't enough 2A little telomerase isn't enough 3A little telomerase isn't enough 4
... Activity Kit ADAM17 Activity Kit TNF-α Converting ... PROTECT FROM LIGHT. AVOID FREEZE/THAW CYCLES. The ... and sensitive assay designed to measure human ... samples and for screening enzyme inhibitors. An ...
... unique agarose-digesting enzyme developed by Promega for ... or RNA from agarose gels. The enzyme ... (LMP) agarose melted at 6575C does not ... temperature before hydrolysis. Simply place the tube ...
...
... FREEZE. Nuclear matrix proteins (NMPs) make up the ... associated with such functions as DNA replication, RNA ... matrix has been shown to be highly insoluble ... that cell death releases soluble nuclear matrix proteins ...
Biology Products: